ANAPTYSBIO, INC. Non Peo Neo Avg Total Comp Amt
ANAPTYSBIO, INC. (ANAB) reported Non Peo Neo Avg Total Comp Amt of $2.19 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-06-29.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-06-29
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $2.19M DEF 14A · filed 2026-06-29 |
| 2024-12-31 | $3.91M DEF 14A · filed 2026-06-29 |
| 2023-12-31 | $2.35M DEF 14A · filed 2026-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |